PT886

Courtney Van Houzen, PharmD, discusses bringing bispecific antibody treatments to community settings, inspired by a patient's need for continuity of care. Promising efficacy and safety of fianlimab and cemiplimab in advanced melanoma is highlighted. Inavolisib plus palbociclib and fulvestrant gains FDA approval for HR+/HER2- PIK3CA-mutated breast cancer. Talazoparib plus enzalutamide shows survival improvement in mCRPC. The TWINPEAK trial initiates with PT886 and pembrolizumab for gastric and GEJ cancers.

The TWINPEAK trial (NCT05482893) has dosed its first patient, evaluating PT886 combined with pembrolizumab for gastric and GEJ cancers. PT886 targets claudin 18.2 and CD47 to enhance immune response. The study is a multicenter, open-label, phase 1/2 trial assessing safety, tolerability, and efficacy in advanced gastric, GEJ, and pancreatic cancers. PT886 has FDA orphan drug designation for pancreatic cancer and fast track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma.

Phanes Therapeutics announced the first patient dosed in the PT886 clinical study combined with Merck's KEYTRUDA® for gastric and gastroesophageal junction cancers. PT886, a first-in-class bispecific antibody, targets claudin 18.2 and CD47, and is being evaluated in various cancer treatments.

First patient dosed in Phanes Therapeutics' clinical study of PT886 combined with Merck's KEYTRUDA for gastric and gastroesophageal junction cancers. PT886, a first-in-class bispecific antibody, targets claudin 18.2 and CD47, and is also being evaluated in pancreatic cancers.

Phanes Therapeutics announced the first patient dosed in PT886 clinical study, a bispecific antibody targeting claudin 18.2 and CD47, in combination with chemotherapy for pancreatic and gastric cancers. The TWINPEAK study evaluates PT886's safety and efficacy in advanced or metastatic cases. PT886 has FDA orphan drug and Fast Track designations.